A Population Pharmacokinetic Model Incorporating Saturable Pharmacokinetics and Autoinduction for High Rifampicin Doses

Accumulating evidence suggests that increasing doses of rifampicin may shorten tuberculosis treatment. The PanACEA HIGHRIF1 trial assessed safety, pharmacokinetics, and antimycobacterial activity of rifampicin at doses up to 40 mg/kg. Eighty‐three pulmonary tuberculosis patients received 10, 20, 25,...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clin Pharmacol Ther
Hauptverfasser: Svensson, Robin J., Aarnoutse, Rob E., Diacon, Andreas H., Dawson, Rodney, Gillespie, Stephen H., Boeree, Martin J., Simonsson, Ulrika S.H.
Format: Artigo
Sprache:Inglês
Veröffentlicht: John Wiley and Sons Inc. 2017
Schlagworte:
Research
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5888114/
https://ncbi.nlm.nih.gov/pubmed/28653479
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpt.778
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge